2009—2021年全球耳念珠菌病的研究进展

摘要/Abstract

摘要： 耳念珠菌是一种近年来新出现的致病性真菌,可引起严重的侵袭性感染,病死率高。通过对已报道的265例患者资料分析,发现耳念珠菌感染患者常见男性,分离株主要来自血液、尿液和耳道、导管等。耳念珠菌感染患者往往伴有基础疾病,以糖尿病、高血压、肺部疾病为主。危险因素包括既往使用过广谱抗生素或抗真菌药物、内置导管、侵入性医疗操作等。该文对全球耳念珠菌感染以及新冠病毒肺炎合并耳念珠菌感染的情况进行报道,对全面了解耳念珠菌临床特征、诊断及治疗具有重要意义。

中图分类号:

R519.3

王颖, 张园, 秦琴, 薛博仁, 王贺. 2009—2021年全球耳念珠菌病的研究进展[J]. 中国真菌学杂志, 2023, 18(4): 381-384.

参考文献

[1] SATOH K, MAKIMURA K, HASUMI Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital[J]. Microbiol Immunol, 2009,53(1):41-44.
[2] LEE W G, SHIN J H, UH Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris[J]. J Clin Microbiol, 2011,49(9):3139-3142.
[3] BOLUKBASI Y, ERKOSE G G, ORHUN G, et al. First case of COVID-19 positive Candida auris fungemia in Turkey[J]. Mikrobiyol Bul, 2021,55(4):648-655.
[4] MOIN S, FAROOQI J, RATTANI S, et al. C. auris and non-C. auris candidemia in hospitalized adult and pediatric COVID-19 patients; single center data from Pakistan[J]. Med Mycol, 2021,59(12):1238-1242.
[5] HINRICHS C, WIESE-POSSELT M, GRAF B, et al. Successful control of Candida auris transmission in a German COVID-19 intensive care unit[J]. Mycoses, 2022,65(6):643-649.
[6] Magnasco L, Mikulska M, Giacobbe D R, et al. Spread ofcarbapenem-resistant gram-negatives and Candida auris during the COVID-19 pandemic in critically Ill patients: One step back in antimicrobial stewardship[J]. Microorganisms, 2021,9(1):95.
[7] SENOK A, ALFARESI M, KHANSAHEB H, et al. Coinfections in patients hospitalized with COVID-19: A descriptive study from the united arab emirates[J]. Infect Drug Resist, 2021,14:2289-2296. DOI:10.2147/IDR.S314029.
[8] PRESTEL C, ANDERSON E, FORSBERG K, et al. Candida auris outbreak in a COVID-19 specialty care unit-Florida, July-August 2020[J]. MMWR Morb Mortal Wkly Rep, 2021,70(2):56-57.
[9] VILLANUEVA-LOZANO H, TREVINO-RANGEL R J, GONZALEZ G M, et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico[J]. Clin Microbiol Infect, 2021, 27(5):813-816.
[10] RODRIGUEZ J Y, LE PAPE P, LOPEZ O, et al. Candida auris: A latent threat to critically ill patients with coronavirus disease 2019[J]. Clin Infect Dis, 2021,73(9): e2836-e2837.
[11] ZUO T, ZHAN H, ZHANG F, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge[J]. Gastroenterology, 2020,159(4):1302-1310.
[12] CHOWDHARY A, TARAI B, SINGH A, et al. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April-July 2020[J]. Emerg Infect Dis, 2020,26(11):2694-2696.
[13] NOBREGA D A J J, BRANDAO I B, FRANCISCO E C, et al. Axillary digital thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil[J]. Mycoses, 2021,64(9):1062-1072.
[14] ALLAW F, KARA Z N, IBRAHIM A, et al. First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon[J]. Pathogens, 2021,10(2):157.
[15] 徐英春, 黄晶晶, 肖盟, 等. 中国耳念珠菌临床感染现状[J]. 协和医学杂志, 2019,10(5):442-445.
[16] WANG X, BING J, ZHENG Q, et al. The first isolate of Candida auris in China: clinical and biological aspects[J]. Emerg Microbes Infect, 2018,7(1):93.
[17] TIAN S, RONG C, NIAN H, et al. First cases and risk factors of super yeast Candida auris infection or colonization from Shenyang, China[J]. Emerg Microbes Infect, 2018,7(1):128.
[18] TANG H J, LAI C C, LAI F J, et al. Emergence of multidrug-resistant Candida auris in Taiwan[J]. Int J Antimicrob Agents, 2019,53(5):705-706.
[19] BING J, WANG S, XU H, et al. A case of Candida auris candidemia in Xiamen, China, and a comparative analysis of clinical isolates in China. Mycology,2021,13(1):68-75.
[20] 宁永忠. 成人耳念珠菌感染诊治防控专家共识[J]. 临床检验杂志, 2020,38(8):564-570.
[21] KORDALEWSKA M, ZHAO Y, LOCKHART S R, et al. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris[J]. J Clin Microbiol, 2017,55(8):2445-2452.
[22] VALLABHANENI S, KALLEN A, TSAY S, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-united states, May 2013-August 2016[J]. Am J Transplant, 2017,17(1):296-299.
[23] LOCKHART S R, ETIENNE K A, VALLABHANENI S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses[J]. Clin Infect Dis, 2017,64(2):134-140.
[24] SHARMA C, KUMAR N, PANDEY R, et al. Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation[J]. New Microbes New Infect, 2016,13:77-82.DOI:10.1016/j.nmni.2016.07.003.
[25] 美国疾病控制和预防中心.耳念珠菌. 2020-05-29. https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html.
[26] CHEN Y, ZHAO J, HAN L, et al. Emergency of fungemia cases caused by fluconazole-resistant Candida auris in Beijing, China[J]. J Infect, 2018,77(6):561-571.
[27] 邴健. 耳念珠菌耐药机制研究进展[J]. 菌物学报, 2020,39(11):2120-2130.
[28] WRING S, BORROTO-ESODA K, SOLON E, et al. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral[(14)C]. SCY-078 in albino and pigmented rats[J]. Antimicrob Agents Chemother, 2019,63(2):e02119-18.
[29] HAMAD A, CHEN Y, KHAN M A, et al. Schiff bases of sulphonamides as a new class of antifungal agent against multidrug-resistant Candida auris[J]. Microbiologyopen, 2021,10(4): e1218.
[30] KOVACS R, NAGY F, TOTH Z, et al. The neosartorya fischeri antifungal protein 2(NFAP2): A new potential weapon against multidrug-resistant Candida auris biofilms[J]. Int J Mol Sci, 2021,22(2):771.